Diabetes Drug vs Weight Loss Drug
Ozempic (semaglutide) and Zepbound (tirzepatide) are different molecules with different FDA indications—diabetes vs weight loss. Zepbound shows higher weight loss.
See what users who've tried both medications say about effectiveness, side effects, and insurance.
Prices re-read November 18, 2026
Ozempic costs $349 every 4 weeks (about $378.08 a month) at NovoCare / Wegovy Direct, the cheapest verified Ozempic price among the providers our tracker re-read in the last 36 hours. Zepbound costs $1,259 a month, month to month at RxION Health, the cheapest verified Zepbound price among the providers our tracker re-read in the last 36 hours. Compounded semaglutide injections start at $79 a month, month to month, at Embody; the cheapest month-to-month prices are $79 at Embody, $99 at Eden and $99 at FlatRx among the 45 providers whose semaglutide prices our tracker re-read in the last 36 hours. Compounded tirzepatide injections start at $118 a month, month to month, at FlatRx; the cheapest month-to-month prices are $118 at FlatRx, $129 at Eden and $129 at Embody among the 43 providers whose tirzepatide prices our tracker re-read in the last 36 hours. Compounded medication is not FDA-approved. Prices read on each provider's own site on November 18, 2026.
$349 every 4 weeks (about $378.08 a month)
at NovoCare / Wegovy DirectRead on November 18, 2026 at 12:41 UTC on novocare.com/pharmacy.html
Cheapest verified Ozempic price, as the provider words it.
$1,259 a month, month to month
at RxION HealthRead on November 18, 2026 at 12:50 UTC on tryrxion.com/weight-management/zepbound
Cheapest verified Zepbound price, as the provider words it.
Cheapest month-to-month prices, one per provider, ordered by price alone (45 providers re-read).
Cheapest month-to-month prices, one per provider, ordered by price alone (43 providers re-read).
Read by our tracker on each provider’s own site. AllGLP1 may earn a commission if you sign up through a link above; it never changes the prices shown or their order.
Side-by-side comparison of reported experiences
| Feature | Ozempic | Zepbound | Source Notes |
|---|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide | Single vs Dual agonist |
| Mechanism | GLP-1 Only | Dual GIP/GLP-1 | Zepbound targets two pathways |
| Typical Weight Loss | ~10% | 20.2% | SURMOUNT-5 head-to-head weight loss data |
| Primary Indication | Type 2 Diabetes | Weight Loss | FDA-approved target uses |
| 2026 List Price | $968/mo | $1,060/mo | Novo vs Lilly list pricing |
| Self-Pay Options | NovoCare | LillyDirect Vials | Self-pay program availability |
| Cardiovascular Data | Proven Benefit | 42% MACE reduction* | *Nature Medicine 2025 (T2D population) |
| Titration Period | 8-12 weeks | 20 weeks | Standard FDA titration schedules |
Single vs Dual agonist
Zepbound targets two pathways
SURMOUNT-5 head-to-head weight loss data
FDA-approved target uses
Novo vs Lilly list pricing
Self-pay program availability
*Nature Medicine 2025 (T2D population)
Standard FDA titration schedules
Figures in this table were typed when the page was written and may be out of date; today's verified prices are in the cost box above.
Data from the SURMOUNT-5 & Nature Medicine (2025) (NEJM / Nature Medicine)
Ozempic (semaglutide) and Zepbound (tirzepatide) are often compared for weight loss. While Ozempic is a GLP-1 receptor agonist, Zepbound is a dual GIP/GLP-1 receptor agonist. Recent head-to-head clinical data (SURMOUNT-5) and real-world studies provide a direct comparison of their weight-loss potency.
| Comparison Metric | Ozempic | Zepbound |
|---|---|---|
| Max Weight Loss (%) | 13.7% | 20.2% |
| HbA1c Reduction (%) | -2.1% | -2.30% |
| Cardiovascular Risk | Proven | 42% MACE reduction* |
| Mechanism | GLP-1 Only | Dual GIP/GLP-1 |
| Lost >20% Body Weight | 28.1% | 52.5% |
"Clinical data from the SURMOUNT-5 trial confirms that Zepbound (tirzepatide) is significantly more effective than semaglutide for weight loss. Additionally, 2025 Nature Medicine data suggests tirzepatide may offer superior cardiovascular protection in diabetic populations. However, Ozempic remains the most studied and widely covered GLP-1 for diabetes specifically."
Results were statistically significant (p < 0.001) across all primary endpoints.
Latest verification performed January 2026.
Answer these 3 questions to see your best match:
Take our 90-second quiz for personalized provider recommendations ranked by your insurance + budget.
Start QuizPatient-reported side effect patterns
Drawing from patient-reported strategies
Real questions from Ozempic users
Common questions from Ozempic users
Not sure which is right for you?
🎯Take Our 2-Minute Quiz